EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.
Alessia AlunnoAurélie NajmPedro M MachadoHeidi BertheussenGerd R BurmesterFrancesco CarubbiGabriele De MarcoRoberto GiacomelliOlivier HermineJohn Dudley IsaacsIsabelle Koné-PautCésar Magro-ChecaIain McInnesPier Luigi MeroniLuca QuartuccioAthimalaipet V RamananManuel Ramos-CasalsJavier Rodríguez CarrioHendrik Schulze-KoopsTanja Alexandra StammSander W TasBenjamin TerrierDennis G McGonagleXavier MariettePublished in: Annals of the rheumatic diseases (2021)
Multifactorial pathophysiological mechanisms, including immune abnormalities, play a key role in COVID-19. The efficacy of glucocorticoids in cases requiring oxygen therapy suggests that immunomodulatory treatment might be effective in COVID-19 subsets. Involvement of rheumatologists, as systemic inflammatory diseases experts, should continue in ongoing clinical trials delineating optimal immunomodulatory therapy utilisation in COVID-19.